|
1
|
American Cancer Society: Breast Cancer
Facts & Figures 2013–2014. American Cancer Society; Atlanta,
GA: 2013
|
|
2
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heitz F, Harter P, Lueck HJ,
Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A and
du Bois A: Triple negative and HER2-overexpressing breast cancers
exhibit an elevated risk and an earlier occurrence of cerebral
metastases. Eur J Cancer. 45:2792–2798. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zasadil LM, Andersen KA, Yeum D, Rocque
GB, Wilke LG, Tevaarwerk AJ, Raines RT, Burkard ME and Weaver BA:
Cytotoxicity of paclitaxel in breast cancer is due to chromosome
missegregation on multipolar spindles. Sci Transl Med.
6:229ra432014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jamdade VS, Sethi N, Mundhe NA, Kumar P,
Lahkar M and Sinha N: Therapeutic targets of triple-negative breast
cancer: A review. Br J Pharmacol. 172:4228–4237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim VN and Nam JW: Genomics of microRNA.
Trends Genet. 22:165–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang F, Zhang W, Shen Y and Guan X:
Identification of dysregulated microRNAs in triple-negative breast
cancer (review). Int J Oncol. 46:927–932. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ghelani HS, Rachchh MA and Gokani RH:
MicroRNAs as newer therapeutic targets: A big hope from a tiny
player. J Pharmacol Pharmacother. 3:217–227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peña-Chilet M, Martínez MT, Pérez-Fidalgo
JA, Peiró-Chova L, Oltra SS, Tormo E, Alonso-Yuste E,
Martinez-Delgado B, Eroles P, Climent J, et al: MicroRNA profile in
very young women with breast cancer. BMC Cancer. 14:5292014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu G, Liu A, Zhu J, Lei F, Wu S, Zhang X,
Ye L, Cao L and He S: MiR-1207 overexpression promotes cancer stem
cell-like traits in ovarian cancer by activating the Wnt/β-catenin
signaling pathway. Oncotarget. 6:28882–28894. 2015.PubMed/NCBI
|
|
13
|
Nagy ZB, Barták BK, Kalmár A, Galamb O,
Wichmann B, Dank M, Igaz P, Tulassay Z and Molnár B: Comparison of
circulating miRNAs expression alterations in matched tissue and
plasma samples during colorectal cancer progression. Pathol Oncol
Res. 4–Oct;2017.(Epub ahead of print). View Article : Google Scholar
|
|
14
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
organization for research and treatment of cancer, National cancer
institute of the United States, National cancer institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Perez-Neut M, Rao VR and Gentile S:
hERG1/Kv11.1 activation stimulates transcription of p21waf/cip in
breast cancer cells via a calcineurin-dependent mechanism.
Oncotarget. 7:58893–58902. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Singel SM, Cornelius C, Batten K, Fasciani
G, Wright WE, Lum L and Shay JW: A targeted RNAi screen of the
breast cancer genome identifies KIF14 and TLN1 as genes that
modulate docetaxel chemosensitivity in triple-negative breast
cancer. Clin Cancer Res. 19:2061–2070. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Olasz EB, Seline LN, Schock AM, Duncan NE,
Lopez A, Lazar J, Flister MJ, Lu Y, Liu P, Sokumbi O, et al:
MicroRNA-135b regulates leucine zipper tumor suppressor 1 in
cutaneous squamous cell carcinoma. PLoS One. 10:e01254122015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu Z and Wang T: miR-214 promotes the
proliferation and invasion of osteosarcoma cells through direct
suppression of LZTS1. Biochem Biophys Res Commun. 449:190–195.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou W, He MR, Jiao HL, He LQ, Deng DL,
Cai JJ, Xiao ZY, Ye YP, Ding YQ, Liao WT and Liu SD: The
tumor-suppressor gene LZTS1 suppresses colorectal cancer
proliferation through inhibition of the AKT-mTOR signaling pathway.
Cancer Lett. 360:68–75. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lovat F, Ishii H, Schiappacassi M, Fassan
M, Barbareschi M, Galligioni E, Gasparini P, Baldassarre G, Croce
CM and Vecchione A: LZST1 downregulation confers paclitaxel
resistance and is associated with worse prognosis in breast cancer.
Oncotarget. 5:970–977. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang XX, Liu BB, Wu X, Su D, Zhu Z and Fu
L: Loss of leucine zipper putative tumor suppressor 1 (LZTS1)
expression contributes to lymph node metastasis of breast invasive
micropapillary carcinoma. Pathol Oncol Res. 21:1021–1026. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baselga J: Targeting the
phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Oncologist. 1 16 Suppl:S12–S19. 2011. View Article : Google Scholar
|
|
23
|
Carracedo A and Pandolfi PP: The PTEN-PI3K
pathway: Of feedbacks and cross-talks. Oncogene. 27:5527–5541.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Danial NN and Korsmeyer SJ: Cell death:
Critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen ED, Liu B, Yu XS, Xiang ZF and Huang
HY: The effects of miR-1207-5p expression in peripheral blood on
cisplatin-bsed chemosensitivity of primary gallbladder carcinoma.
Onco Targets Ther. 9:3633–3642. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He Y and Liu X: The tumor-suppressor gene
LZTS1 suppresses hepatocellular carcinoma proliferation by
impairing PI3K/Akt pathway. Biomed Pharmacother. 76:141–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang XX, Zhu Z, Su D, Lei T, Wu X, Fan Y,
Li X, Zhao J and Fu L, Dong JT and Fu L: Down-regulation of leucine
zipper putative tumor suppressor 1 is associated with poor
prognosis, increased cell motility and invasion, and
epithelial-to-mesenchymal transition characteristics in human
breast carcinoma. Hum Pathol. 42:1410–1419. 2011. View Article : Google Scholar : PubMed/NCBI
|
